|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
November/December 2008FeaturesCover Story Employers to Unions: See If You Can Do BetterFaced with staggering healthcare costs, some large companies have transferred those liabilities to a voluntary employee beneficiary association. Eager to control employee and retiree benefits, unions gladly have taken on the challenge of running a VEBA. But success in this field is hard won, and to earn it, some unions may be forced to take a harder line with health care professionals and manufacturers than employers did. Health Policy Creating a Pathway Over the Regulatory Chasm: A Fresh StartWith the election over, a clear framework for guiding follow-on biologics to market may soon emerge. But difficult issues of cost, timing, and even terminology are keeping innovators and generic rivals on opposite sides of the fence. Risk Management Strategies Making the Case for Biotechnology Reinsurance (Bio-Re)The inherent difficulty of sustaining the rate of growth in healthcare spending may make biologics a touchstone for government intervention. The author proposes a combined cost-management and care-delivery standard that could lessen that threat. Specialty Pharmacy To Manage Costs of Hemophilia, Patients Need More Than Clotting FactorWith the cost of clotting factor exceeding $50,000 a year, careful management can save payers thousands of dollars per patient. The author writes about the role specialty pharmacy plays in cost management while helping patients achieve better clinical outcomes. Access to Care Copayment Foundations: Help for the UnderinsuredWith focus often placed on the uninsured, many patients who are underinsured fall through the cracks. Copayment foundations look to fill their gaps in coverage. DepartmentsOpeners Unintended ConsequencesThe law of unintended consequences. Editorial Birthday BoomerBoomers: Not ready to retire. Personalized Medicine Role of Genetic Data Emerges in Antismoking EffortGenetics’ influence on quit-smoking drugs. At a Glance Digestive Diseases: Epidemiology, Economics, and the PipelinePrevalence of disease, economics of care, the drug development pipeline, and implications for payers. Drug Track Research, Conferences, and FDA ActionsApprovals, research, conference coverage. Specialty Pharmacy When It Comes to SP, Employer Size MattersStrategies for small, medium, big companies. Employer to Employer When a Negative Becomes a Positive: GIC Bucks the High-Cost TrendState provides liberal but measured access. Trends: Pipeline Biotech Drug Development Jumps 51 Percent in 2 YearsDramatic growth in the biologic pipeline. |
|||||